supp.fit

Niacin and Coenzyme Q10: study protocols

8 study groups took Niacin together with Coenzyme Q10. These are the doses the studies gave. They are not a recommendation.

Niacin: what the research found →

Dose per serving from research: Niacin

8 study groups in 5 studies say how much Niacin participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 25 mg to 50 mg, 88% of 8 study groups.

Daily doseStudy groups
25 mg or less
1
25 mg to 50 mg
7

Dose per serving from research: Coenzyme Q10

8 study groups in 5 studies say how much Coenzyme Q10 participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 50 mg to 100 mg, 88% of 8 study groups.

Daily doseStudy groups
25 mg or less
1
25 mg to 50 mg
0
50 mg to 100 mg
7

Commonly used together

8 of 8 study groups took Niacin and Coenzyme Q10 with something else. Shown: what 3 or more different studies gave.

What was given together, not what works together.

Taken withStudy groups
Riboflavin
7

8 study groups

Study
Nutraceutical approach for the management of cardiovascular risk - a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study
2019 · Nutraceutical combination · Adults aged 18–70 with low cardiovascular risk, in primary cardiovascular prevention, and LDL-C of 130–200 mg/dL
16 mg20 mg12 weeks16
Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy
2007 · Group IV (CoRN for 45 days) · Breast cancer patients undergoing tamoxifen therapy; age and sex not specified
50 mg100 mg45 days—
Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy
2007 · Group V (CoRN for 90 days) · Breast cancer patients undergoing tamoxifen therapy; age and sex not specified
50 mg100 mg90 days—
Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin
2007 · Group IV (CoRN for 45 days) · Breast cancer patients treated with tamoxifen
50 mg100 mg45 days—
Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin
2007 · Group V (CoRN for 90 days) · Breast cancer patients treated with tamoxifen
50 mg100 mg90 days—
Co-enzyme Q10, riboflavin and niacin supplementation on alteration of DNA repair enzyme and DNA methylation in breast cancer patients undergoing tamoxifen therapy
2008 · CoRN supplement plus tamoxifen · Breast cancer patients undergoing tamoxifen therapy
50 mg100 mg——
Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy
2008 · Group IV (CoRN for 45 days) · Breast cancer patients receiving tamoxifen therapy for more than 1 year; age not reported
50 mg100 mg45 days—
Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy
2008 · Group V (CoRN for 90 days) · Breast cancer patients receiving tamoxifen therapy for more than 1 year; age not reported
50 mg100 mg90 days—
Niacin and Coenzyme Q10: study protocols | supp.fit